Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on ALLERGAN PLC
02/23ALLERGAN : An Application for the Trademark "PYLERA" Has Been Filed by Allergan
AQ
02/23ALLERGAN : FDA Acceptance of Medicines360's Filing for supplemental New Drug App..
AQ
02/22ALLERGAN : FDA Acceptance of Medicines360's Filing for supplemental New Drug App..
PR
02/20ALLERGAN : Presents Data at the 2018 American Academy of Dermatology Annual Meet..
AQ
02/17ALLERGAN : Presents Data at the 2018 American Academy of Dermatology (AAD) Annua..
PU
02/16ALLERGAN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
02/15ALLERGAN : An Application for the Trademark "REJUVECROSS" Has Been Filed by Alle..
AQ
02/15ALLERGAN : Trademark Application for "REJUVACROSS" Filed by Allergan
AQ
02/15ALLERGAN : Matthew M. Walsh Appointed Executive Vice President and Chief Financi..
AQ
02/14ALLERGAN : s Forest Labs pays 726m in dividend
AQ
02/13ALLERGAN : Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share..
AQ
02/09ALLERGAN (NYSE : AGN) announces a quarterly dividend of  $0.72
AQ
02/09ALLERGAN : Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share..
PR
02/09GASTROINTESTINAL DRUGS MARKET GLOBAL : This consequently drives the global gastr..
AQ
02/08ALLERGAN : Trademark Application for "TRUETEAR 50 PLUS CLUB" Filed
AQ
02/08ALLERGAN : FDA Approves AVYCAZ® ceftazidime and avibactam for the Treatment of P..
AQ
02/08ARRAY BIOPHARMA : and Allergan Just Scored Big On Phase III Data
AQ
02/07ALLERGAN : up on good migraine drug trials and financial results
AQ
02/07ALLERGAN : ubrogepant meets in Phase III for acute migraine
AQ
02/06ALLERGAN PLC : Results of Operations and Financial Condition, Financial Statemen..
AQ
02/06ALLERGAN : Reports Solid Finish to 2017 with 12% Increase in Fourth Quarter GAAP..
PR
02/06ALLERGAN PLC : to Host Earnings Call
AC
02/06ALLERGAN : Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral ..
PR
02/05ALLERGAN PLC (NYSE : AGN) Files An 8-K Departure of Directors or Certain Officer..
AQ
02/05ALLERGAN : to Present at The Leerink Partners 7th Annual Global Healthcare Confe..
AQ
02/05ALLERGAN : FDA Approves AVYCAZ for the Treatment of Patients with Hospital-Acqui..
AQ
02/05ALLERGAN PLC : Change in Directors or Principal Officers (form 8-K)
AQ
02/05ALLERGAN : Matthew M. Walsh Appointed Executive Vice President and Chief Financi..
PR
02/03ALLERGAN : FDA Approves AVYCAZ (ceftazidime and avibactam) for the Treatment of ..
AQ
02/02ALLERGAN : completes restructuring, pushes hard in China
RE
02/02ALLERGAN : Introduces 'Not Cool vs. Cool' Multi-Channel Campaign for CoolSculpti..
AQ
02/02ALLERGAN : Introduces “Not Cool vs. Cool” Multi-Channel Campaign for..
AQ
02/01ALLERGAN : FDA Approves AVYCAZ® (ceftazidime and avibactam) for the Treatment of..
PR
02/01ALLERGAN : Trademark Application for "JUVEDERM" Filed by Allergan
AQ
02/01ALLERGAN : Trademark Application for "REFRESH FUSION TEARS REPAIR" Filed
AQ
02/01ALLERGAN : An Application for the Trademark "ALLERGAN ACADEMY" Has Been Filed by..
AQ
02/01ALLERGAN : Trademark Application for "PATIENTS OUR VIRTUE" Filed
AQ
02/01ALLERGAN : Trademark Application for "REFRESH TEARS REPAIR" Filed
AQ
02/01ALLERGAN : An Application for the Trademark "REFRESH FUSION REPAIR" Has Been Fil..
AQ
02/01ALLERGAN : to pay Israel's Teva Pharm $700 million to settle dispute
RE
02/01ALLERGAN PLC : Results of Operations and Financial Condition, Other Events (form..
AQ
01/31ALLERGAN : to Present at The Leerink Partners 7th Annual Global Healthcare Confe..
PR
01/31ALLERGAN INTRODUCES "NOT COOL VS. CO : Figure Skater Johnny Weir and Golfer Ian ..
PU
01/26OCULAR DRUG DELIVERY MARKET VOLUME A : Ocular Drug Delivery Market Overview & In..
AQ
01/25AMGEN : European Commission Approves Amgen And Allergan's MVASI® Biosimilar Beva..
AQ
01/23New York City sues drug companies over opioid epidemic
RE
01/22WILLIAM ACKMAN : Ackman cuts staff, shuns limelight as he seeks to turn around f..
RE
01/20ALLERGAN : Factory Mutual Insurance Co. Increases Holdings in Allergan plc (AGN)
AQ
01/19AMGEN : EC approves Amgen's biosimilar Avastin
AQ
01/18ALLERGAN : European Commission Approves Amgen And Allergan's MVASI® (Biosimilar ..
PR
01/17Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS P..
AQ
01/17Allergan Pact Advances -- WSJ
DJ
01/17Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
DJ
01/16Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
DJ
01/16ALLERGAN : Ironwood and Allergan Announce Settlement with Sun Pharma Resolving L..
BU
01/13ALLERGAN : Evolus Files for IPO Ahead of Potential 2018 Approval for Botox Alter..
AQ
01/11ALLERGAN : Trademark Application for "NASH COUNSEL SUPPORT EDUCATION LEADERSHIP"..
AQ
01/11ALLERGAN : 2 Reasons Why Allergan Stock Plunged in 2017
AQ
01/09U.S. pharma executives expect deals to pick up after tax overhaul
RE
01/09ALLERGAN PLC (NYSE : AGN) Files An 8-K Results of Operations and Financial Condi..
AQ
01/08ALLERGAN PLC : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
01/08ALLERGAN : Provides 2018 Preliminary Financial Outlook for Select Income Stateme..
PR
01/08ALLERGAN : to Report Fourth Quarter and Full Year 2017 Earnings and Host Confere..
PR
01/04ALLERGAN : Acknowledges Appeals Court Decision for COMBIGAN®
AQ
01/04ALLERGAN : to Present at the 36th Annual J.P. Morgan Healthcare Conference
AQ
01/04STUDIES FROM ALLERGAN UPDATE CURRENT : Timing and...
AQ
01/03ALLERGAN : to cut over 1,000 jobs as it works to cut costs
RE
01/03ALLERGAN PLC : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
01/03Pershing Square, Valeant to appear in court on insider trading suit settlemen..
RE
01/03Allergan among companies unveiling price hikes
AQ
01/03ALLERGAN PLC (NYSE : AGN) Files An 8-K Entry into a Material Definitive Agreemen..
AQ
01/03Pershing Square, Valeant to appear in court on insider trading suit settlemen..
RE
01/02ALLERGAN PLC : Entry into a Material Definitive Agreement, Material Modification..
AQ
2017Pershing Square, Valeant arrive at settlement split for Allergan lawsuit
RE
2017ALLERGAN : to Present at the 36th Annual J.P. Morgan Healthcare Conference
AQ
1  2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2018 15 196 M
EBIT 2018 7 274 M
Net income 2018 -1 246 M
Debt 2018 22 990 M
Yield 2018 1,83%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,00x
EV / Sales 2019 4,66x
Capitalization 53 014 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 216 $
Spread / Average Target 35%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Matthew M. Walsh Chief Financial Officer & Executive VP
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
James H. Bloem Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-2.56%53 014
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%222 939
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 036
MERCK AND COMPANY-3.02%148 618